Skip to Content

Novoeight Approval History

  • FDA approved: Yes (First approved October 15th, 2013)
  • Brand name: Novoeight
  • Generic name: turoctocog alfa
  • Dosage form: for Intravenous Injection
  • Company: Novo Nordisk
  • Treatment for: Hemophilia A

Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated for use in adults and children with hemophilia A.

Development History and FDA Approval Process for Novoeight

Oct 16, 2013Approval NovoEight (turoctocog alfa) Receives Approval from the FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.